Clinical trial · no report yet · Phase 3
SANOVO
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- NCT05009836 ↗
- Active, not recruiting
- Hutchmed
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Savolitinib; Placebo; Osimertinib
- Arms
- Savolitinib + Osimertinib · Experimental
- Placebo + Osimertinib · Placebo comparator
- Enrollment
- 412 (estimated)
- Primary outcomes
- PFS
- Sponsor
- Hutchmed
- Start
- Sep 6, 2021
- Primary completion
- May 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05009836 · updated Sep 22, 2026